WASHINGTON, Sept. 17, 2024 /PRNewswire/ — The Heart Failure Society of America (HFSA) Board of Directors has named Anuradha Lala-Trindade, MD and Robert J. Mentz, MD as Co-Editors-in-Chief of the Journal of Cardiac Failure, the official journal of HFSA and the Japanese Heart Failure…
Other News
Philips announces FDA approval for enhanced LumiGuide guidewire and marks the 1000th patient treated with its breakthrough 3D device guidance technology
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of the 160cm FDA approved version of its unique LumiGuide endovascular navigation wire. This enhanced LumiGuide guidewire, which utilizes the company’s breakthrough Fiber Optic RealShape (FORS) technology, was used for the first time on a patient by Professor and vascular surgeon Carlos Timaran, MD, an internationally recognized expert in advanced endovascular techniques. He used the technology during a complex aortic aneurism repair operation, marking the 1000th patient treated milestone using FORS technology since first clinical use of the technology in 2020. The introduction of a longer FORS-enabled LumiGuide Navigation Wire enables US clinicians to visualize a broader range of catheters and expands usage of this technology to patients in America treated in centers equipped with LumiGuide.
Boston Scientific Closes Acquisition of Silk Road Medical, Inc.
MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid…
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024 Completion of enrollment expected in Q4 with FDA submission for commercialization anticipated by the end of 2024
Piccolo Medical, Inc. Receives FDA Clearance for ECGuide™ Catheter Guidance Technology
SAN FRANCISCO, Sept. 16, 2024 /PRNewswire/ — Piccolo Medical, Inc. (Piccolo) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its innovative catheter guidance technology, the PM2™ System with ECGuide™ Connector. This technology…
Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7 – in Europe
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus Lightning Bolt™ 7 is designed […]
Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System
Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass. (September 16, 2024) – Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, today announced that it has received certification according to Medical Device Regulation (EU) 2017/745 for SIR-Spheres® […]
Argon Medical Launches CLEANER Vac™ Thrombectomy System to Remove Blood Clot in the Peripheral Venous Vasculature
PLANO, Texas, Sept. 16, 2024 /PRNewswire/ — Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac™ Thrombectomy System for the…
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
Southlake, TX, Sept. 12, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today reported financial results for the first quarter fiscal 2025 ended July 31, 2024 and provided a business update.
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart failure patients with reduced ejection fraction



